Latest & greatest articles for lithium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lithium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lithium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lithium

1. Risk for dementia in lithium treated bipolar disorder patients: a systematic review and meta-analysis

Risk for dementia in lithium treated bipolar disorder patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

2. Predictors of response or non-response to long-term treatment with lithium in bipolar disorders: a systematic review of the literature

Predictors of response or non-response to long-term treatment with lithium in bipolar disorders: a systematic review of the literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

3. Lithium

Lithium Top results for lithium - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lithium The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

4. CRACKCast E160 – Lithium

CRACKCast E160 – Lithium CRACKCast E160 – Lithium - CanadiEM CRACKCast E160 – Lithium In , by Adam Thomas March 19, 2018 This episode of CRACKCast covers Rosen’s Chapter 154, Lithium. You will have a solid approach to lithium overdose after listening to this episode! Shownotes – Rosen’s In Perspective : Lithium was approved for the treatment of bipolar disorder in 1970, and it remains one of the most effective agents for both depressive and manic symptoms. Lithium largely has no effect when (...) given in therapeutic doses to patients without mood disorders. [1] How does lithium work? From Rosen’s: “ In spite of long-term therapeutic use, the mechanism by which lithium acts is still not fully understood. Its efficacy in the treatment of psychiatric illnesses is thought to be due to the modulation of neurotransmitters, which has downstream effects through cell signaling and molecular mechanisms.” [2] What is the clinical presentation of lithium toxicity? Acute toxicity = GI symptoms

2018 CandiEM

5. Lithium Use in Pregnancy and the Risk of Cardiac Malformations. (PubMed)

Lithium Use in Pregnancy and the Risk of Cardiac Malformations. There has been concern that exposure to lithium early in pregnancy may be associated with a marked increase in the risk of Ebstein's anomaly (a right ventricular outflow tract obstruction defect) in infants and overall congenital cardiac defects, but data are conflicting and limited.We conducted a cohort study involving 1,325,563 pregnancies in women who were enrolled in Medicaid and who delivered a live-born infant between 2000 (...) and 2010. We examined the risk of cardiac malformations among infants exposed to lithium during the first trimester as compared with unexposed infants and, in secondary analyses, with infants exposed to another commonly used mood stabilizer, lamotrigine. Risk ratios and 95% confidence intervals were estimated with control for psychiatric and medical conditions, medications, and other potential confounders.Cardiac malformations were present in 16 of the 663 infants exposed to lithium (2.41%), 15,251

Full Text available with Trip Pro

2017 NEJM

6. Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses

Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses Julie M. Coe, DDS, MS, MBA . Overview Systematic Review Conclusion Lithium disilicate (LD) single crowns indicated excellent outcome in 1 through 5 years (5-year cumulative survival, 97.8%) compared with LD fixed prostheses with only a fair outcome (5-year cumulative survival, 78.1

2017 ADA Center for Evidence-Based Dentistry

7. Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses

Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) specialties and certifying boards Evidence Education * Associated Topics Lithium disilicate single crowns demonstrate favorable clinical outcomes in 1 through 5 years compared with lithium disilicate fixed prostheses Julie M. Coe, DDS, MS, MBA . Overview Systematic Review Conclusion Lithium disilicate (LD) single crowns indicated excellent outcome in 1 through 5 years (5-year cumulative survival, 97.8%) compared with LD fixed prostheses with only a fair outcome (5-year cumulative survival, 78.1

2017 ADA Center for Evidence-Based Dentistry

8. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.

The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. Since the discovery of antidepressants, new treatments have emerged with fewer side effects but no greater efficacy. Glycogen synthase kinase 3 β (GSK-3β), a kinase known for its activity on glycogen synthesis, has in the last few years raised growing interest in biological psychiatry. Several efficient treatments in major depression have (...) an inhibitory effect on this kinase, which could be targeted in new mood disorder treatments.The aim of this review is to summarize findings concerning the intracellular pharmacologic effects of GSK-3β inhibitors on mood. After a brief description of the intracellular transduction pathways implicated in both GSK-3β and mood disorders, we reviewed the results demonstrating GSK-3β involvement in the effects of lithium and ketamine.GSK-3β can be inhibited through several mechanisms such as serine

2017 L'Encephale

10. GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder (PubMed)

GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder Genetic variants and medication adherence have been identified to be the main factors contributing to lithium treatment response in bipolar disorders.To simultaneously examine effects of variant glutamate decarboxylase-like protein 1 (GADL1) and medication adherence on response to lithium maintenance treatment in Han Chinese patients with bipolar I (BPI) disorder.Frequencies (...) of manic and depressive episodes between carriers and non-carriers of the effective GADL1 rs17026688 T allele during the cumulative periods of off-lithium, poor adherence to lithium treatment and good adherence to lithium treatment were compared in Han Chinese patients with BPI disorder (n=215).GADL1 rs17026688 T carriers had significantly lower frequencies of recurrent affective episodes than non-T carriers during the cumulative period of good adherence, but not during those of poor adherence.GADL1

Full Text available with Trip Pro

2016 BJPsych open

11. Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study (PubMed)

Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study Lithium inhibits glycogen synthase kinase-3, which is an enzyme involved in the pathogenesis of cancer.To investigate the association between lithium and cancer risk in patients with bipolar disorder.A retrospective cohort study was designed using the National Health Insurance Research Database (NHIRD) in Taiwan. Patients using lithium comprised the index drug group and patients using anticonvulsants (...) only comprised the control group. Time-dependent Cox regression was used to evaluate the hazard ratios (HRs) for risk of cancer.Compared with anticonvulsant-only exposure, lithium exposure was associated with significantly lower cancer risk (HR = 0.735, 95% CI 0.554-0.974). The hazard ratios for the first, second and third tertiles of the cumulative defined daily dose were 0.762 (95% CI 0.516-1.125), 0.919 (95% CI 0.640-1.318) and 0.552 (95% CI 0.367-0.831), respectively.Lithium is associated

Full Text available with Trip Pro

2016 EvidenceUpdates

12. Outcomes: Reconsidering risk factors for renal dysfunction in lithium-treated patients

Outcomes: Reconsidering risk factors for renal dysfunction in lithium-treated patients Reconsidering risk factors for renal dysfunction in lithium-treated patients | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Reconsidering risk factors for renal dysfunction in lithium-treated patients Article Text Further commentaries Electronic pages Outcomes Reconsidering risk factors for renal dysfunction in lithium-treated patients Alberto

2016 Evidence-Based Mental Health

13. Lithium for schizophrenia. (PubMed)

Lithium for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary anti-psychotic drug treatment. In these cases, various add-on medications are used, among them lithium.To assess whether:1. Lithium alone is an effective treatment for schizophrenia, schizophrenia-like psychoses and schizoaffective psychoses; and2. Lithium augmentation of antipsychotic medication is an effective treatment for the same illnesses.In July 2012, we searched (...) the Cochrane Schizophrenia Group's Study-Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. This search was updated on January 20, 2015. For the first version of the review, we also contacted pharmaceutical companies and authors of relevant studies to identify further trials and obtain original participant data.Randomised controlled trials (RCTs) of lithium compared with antipsychotics or placebo

2015 Cochrane

14. Hemodialysis for lithium poisoning. (PubMed)

Hemodialysis for lithium poisoning. Lithium salts, particularly lithium carbonate, are frequently used to treat bipolar disorder and mania. Lithium poisoning, which can occur as a result of reduced renal elimination, prescribing error, drug-drug interactions, or deliberate overdosage, produces neurologic injury that can be permanent. Hemodialysis is often recommended to treat lithium poisoning. Although hemodialysis clearly enhances the elimination of lithium, it is unclear whether (...) this translates into improved patient outcomes. Evidence from observational studies, generally of low methodological quality, shows similar outcomes in patients managed with or without the use of hemodialysis.To determine whether hemodialysis, applied in addition to standard therapy, reduces the likelihood, severity, or duration of neurological sequelae following lithium poisoning.We ran the search on 15 May 2015. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register

2015 Cochrane

15. Lithium for bipolar disorder: prevent adverse effects

Lithium for bipolar disorder: prevent adverse effects Prescrire IN ENGLISH - Spotlight ''Lithium for bipolar disorder: prevent adverse effects '', 1 March 2014 {1} {1} {1} | | > > > Lithium for bipolar disorder: prevent adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Lithium for bipolar disorder: prevent adverse effects Lithium (...) is the reference drug for stabilising the mood of patients suffering from bipolar disorder. But it needs to be carefully dosed since there is a very narrow margin between the therapeutic dose and the appearance of sometimes severe adverse effects. With careful adjustment of the dosage the risk of adverse effects remains low. Lithium is a reference drug for stabilising the mood of patients suffering from bipolar disorders and preventing acute suicidal and manic episodes. But there is a fine line – a narrow

2014 Prescrire

16. Need exists for genetic predictors of lithium response

Need exists for genetic predictors of lithium response Need exists for genetic predictors of lithium response | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Need exists for genetic predictors of lithium response Article Text Causes and risk factors Need exists for genetic predictors of lithium response James B Potash 1 , Thomas G Schulze 2 Statistics from Altmetric.com What is already known on this topic? Patients with bipolar

2014 Evidence-Based Mental Health

17. Lithium

Lithium USE OF LITHIUM IN PREGNANCY 0344 892 0909 USE OF LITHIUM IN PREGNANCY (Date of issue: May 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Lithium is a mood stabilising agent licensed for the treatment and prophylaxis (...) of mania, bipolar disorder and recurrent depression, and the treatment of aggressive or mutilating behaviour. Lithium levels need to be monitored regularly in the non-pregnant patient and more frequently throughout pregnancy and the postnatal period. The majority of studies have not suggested an overall increased risk of congenital malformation, although a possible increased risk of cardiac defects has been found. An early retrospective study suggested an association between in utero lithium exposure

2014 UK Teratology Information Service

18. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis

Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis Cipriani A, Hawton K, Stockton S, Geddes JR CRD summary This updated review concluded that lithium was effective in reducing the risk of suicide in people with mood disorders such as depression (...) and bipolar disorder. The conclusion reflects the evidence presented and is likely to be reliable. Authors' objectives To update a previous review that assessed the effectiveness of lithium in preventing suicide and self harm in people with mood disorders. Searching MEDLINE, EMBASE, CINAHL, PsycINFO, LILACS and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to January 2013. Search terms were reported. No language restrictions were applied. Trial databases

Full Text available with Trip Pro

2013 DARE.

19. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. (PubMed)

Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. To assess whether lithium has a specific preventive effect for suicide and self harm in people with unipolar and bipolar mood disorders.Systematic review and meta-analysis.Medline, Embase, CINAHL, PsycINFO, CENTRAL, web based clinical trial registries, major textbooks, authors of important papers and other experts in the discipline, and websites of pharmaceutical companies that manufacture (...) lithium or the comparator drugs (up to January 2013).Randomised controlled trials comparing lithium with placebo or active drugs in long term treatment for mood disorders.Two reviewers assessed studies for inclusion and risk of bias and extracted data. The main outcomes were the number of people who completed suicide, engaged in deliberate self harm, and died from any cause.48 randomised controlled trials (6674 participants, 15 comparisons) were included. Lithium was more effective than placebo

Full Text available with Trip Pro

2013 BMJ

20. Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium (PubMed)

Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium Lithium salts, once the mainstay of therapy for bipolar disorder, have tolerability issues at a higher dosage that often limit adherence. The authors investigated the comparative effectiveness of more tolerable dosages of lithium as part of optimized personalized treatment (OPT).The authors randomly assigned 283 (...) bipolar disorder outpatients to 6 months of open, flexible, moderate dosages of lithium plus OPT or to 6 months of OPT alone. The primary outcome measures were the Clinical Global Impression Scale for Bipolar Disorder-Severity (CGI-BP-S) and "necessary clinical adjustments" (medication adjustments per month). Secondary outcome measures included mood symptoms and functioning. The authors also assessed sustained remission (defined as a CGI-BP-S score ≤2 for 2 months) and treatment with second-generation

2013 EvidenceUpdates